Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in Restrictive Chronic Lung Allograft Dysfunction
NCT03359863Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Mar 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirfenidone in restrictive allograft syndrome (RAS), sponsored by University of California, San Francisco. Started Mar 2018; status: completed.
02
Drugs
pirfenidone
03
Conditions
restrictive allograft syndrome (RAS)
Beyond the preview
Go deeper on NCT03359863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03359863.